Isabel Leroux-Roels

Ghent University Hospital

Belgium

Research Interests

Explore related searches

Professors in Belgium

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

Articles (10)

Year:

2024

Year:

2024

Year:

2023

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Collaborators (4)

Inge Gyssens

Professor of Infectious Diseases

Hasselt University

BELGIUM

View details

Vesna Blazevic

University of Tampere

FINLAND

View details

Judith DEL CAMPO

Head of Immunology Department

FRANCE

View details

Jan J. De Waele

BELGIUM

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Isabel Leroux-Roels

Research Interests

Explore related searches

Contact this professor

Articles (10)

Safety and Immunogenicity of a Carbohydrate Fatty Acid Monosulphate Ester Adjuvant Combined with a Low-Dose Quadrivalent Split-Virion Inactivated Influenza Vaccine: A Randomised, Observer-Blind, Active-Controlled, First-in-Human, Phase 1 Study

Environmental sustainability and antimicrobials: an underestimated problem with far-reaching consequences

Selective digestive decontamination - Pro

Practice testing of generic quality indicators for responsible antibiotic use in nine hospitals in the Dutch-Belgian border area.

The role of cell-mediated immunity against influenza and its implications for vaccine evaluation.

Safety and immunogenicity of a respiratory syncytial virus prefusion F (RSVPreF3) candidate vaccine in older adults: phase I/II randomized clinical trial.

Randomized, Double-Blind, Reference-Controlled, Phase 2a Study Evaluating the Immunogenicity and Safety of OVX836, A Nucleoprotein-Based Influenza Vaccine.

Implementation of the Infection Risk Scan (IRIS) in nine hospitals in the Belgian-Dutch border region (i-4-1-Health project).

A randomized, double-blind, placebo-controlled, dose-escalating phase I trial to evaluate safety and immunogenicity of a plant-produced, bivalent, recombinant norovirus-like particle vaccine

Efficacy and safety of the CVnCoV SARS-CoV-2 mRNA vaccine candidate in ten countries in Europe and Latin America (HERALD) : a randomised, observer-blinded, placebo-controlled, phase 2b/3 trial

Collaborators (4)

Inge Gyssens

Vesna Blazevic

Judith DEL CAMPO

Jan J. De Waele

Make your next move.